Wegovy SELECT Trial: What It Showed About Heart Attack and Stroke Risk

    Wegovy SELECT Trial: What It Showed About Heart Attack and Stroke Risk

    In the SELECT trial, Wegovy cut major heart events 20% (8.0% to 6.5%). Which outcomes were significant, side effects, the label and Medicare coverage.

    Written by Diana Gangan. Updated November 9, 2026.

    Yes, Wegovy lowered the risk of heart attack, stroke and heart-related death in the SELECT trial, by 20% in relative terms, in adults who already had heart or blood vessel disease and were overweight or had obesity but did not have diabetes. In absolute terms, 6.5% of people on Wegovy had one of those events over about three and a half years, compared with 8.0% on placebo, a difference of 1.5 percentage points. That combined result is what led the FDA to approve Wegovy in March 2024 to reduce the risk of major cardiovascular events. But the details matter: when the three parts of the combined outcome are looked at separately, only non-fatal heart attacks fell by a statistically significant amount; the drops in cardiovascular death and stroke could have been due to chance. The trial was designed and funded by Novo Nordisk, which makes Wegovy. Below: who was enrolled, the outcome table, later analyses, the label and Medicare coverage as of November 2026.

    Wegovy and the Heart: The Short Answer

    1. 1SELECT result: major cardiovascular events fell from 8.0% to 6.5% (hazard ratio 0.80), a 20% relative reduction.
    2. 2Only one part was clearly significant: non-fatal heart attack (HR 0.72); cardiovascular death and stroke were not.
    3. 3Who it applies to: adults with established cardiovascular disease plus obesity or overweight, without diabetes in the trial.
    4. 4FDA status: approved for heart-risk reduction in March 2024; the May 2026 label extends this to Wegovy tablets.
    5. 5Side effects: 16.6% stopped for side effects versus 8.2% on placebo; heart rate rises slightly on average.
    6. 6Medicare: Part D plans may cover Wegovy for the heart indication; weight-loss-only use is handled separately.

    What Was the Wegovy SELECT Trial?

    SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a large placebo-controlled randomized trial, registered as NCT03574597. It tested whether once-weekly semaglutide 2.4 mg, the active ingredient and dose in Wegovy, could prevent heart attacks and strokes in people who already had cardiovascular disease. Both groups continued standard care. The trial ran from October 2018 to June 2023 at 804 sites in 41 countries and was presented at the American Heart Association meeting in November 2023, with the main results published in the New England Journal of Medicine.

    A total of 17,604 people were randomized: 8,803 to semaglutide and 8,801 to placebo. Average follow-up was 39.8 months, and people were on the drug for an average of 34.2 months. About 96.9% completed the trial. Novo Nordisk sponsored it. If you are new to how the drug works, see what Wegovy does in the body.

    Who Was in the Trial, and Who Wasn't?

    To join, people had to be 45 or older, have a body mass index (BMI) of 27 or higher, and have established cardiovascular disease, meaning a previous heart attack, a previous stroke, and/or peripheral artery disease (narrowed arteries, usually in the legs). People with diabetes were excluded. According to the FDA label, the average participant was 62 years old with a BMI of 33, and 72% were men.

    That shapes who the results apply to. SELECT does not tell us whether Wegovy prevents heart attacks in people with obesity who have never had heart disease, and it was not a study of people with type 2 diabetes.

    Does Wegovy Reduce Heart Attack Risk?

    The trial's main outcome, called MACE (major adverse cardiovascular events), counted the first of three events: death from cardiovascular causes, a non-fatal heart attack, or a non-fatal stroke. MACE happened in 569 people on semaglutide (6.5%) and 701 on placebo (8.0%). The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90 and P<0.001. A hazard ratio compares event rates over time; 0.80 means about 20% fewer events, and a confidence interval entirely below 1.0 means chance is an unlikely explanation.

    Relative and absolute numbers tell different stories. A 20% relative reduction sounds large, but in absolute terms the gap was 1.5 percentage points over a little more than three years. Put another way, about 92 to 94 out of every 100 people in either group did not have one of these events during the trial, and about 1 or 2 more people in every 100 avoided one on Wegovy. That is meaningful for people with heart disease, but not a guarantee.

    Which SELECT Outcomes Were Statistically Significant?

    Headlines often blur the components together. Some articles reported that Wegovy cut heart attack risk by 28%; that figure comes from the non-fatal heart attack component (HR 0.72), not the trial's main result. The table below combines figures from the NEJM paper and the FDA label. Label rows count fatal and non-fatal events.

    SELECT trial outcomes: Wegovy (semaglutide 2.4 mg) vs placebo

    Outcome
    Wegovy
    Placebo
    Hazard ratio (95% CI)
    Statistically significant?

    MACE (primary outcome)

    6.5%

    8.0%

    0.80 (0.72-0.90)

    Yes (P<0.001)

    Cardiovascular death

    Not shown in label table

    Not shown in label table

    0.85 (0.71-1.01)

    No (P=0.07)

    Non-fatal heart attack (NEJM)

    -

    -

    0.72 (0.61-0.85)

    Yes

    Fatal or non-fatal heart attack (label)

    2.8%

    3.8%

    0.72

    Yes

    Non-fatal stroke (NEJM)

    -

    -

    0.93 (0.74-1.15)

    No

    Fatal or non-fatal stroke (label)

    1.8%

    2.0%

    0.89 (0.72-1.11)

    No

    Death from any cause (NEJM)

    -

    -

    0.81 (0.71-0.93)

    Secondary outcome; supportive only

    Heart failure composite (NEJM)

    -

    -

    0.82 (0.71-0.96)

    Secondary outcome; supportive only

    Heart failure hospitalization or urgent visit (label)

    1.1%

    1.4%

    0.79 (0.60-1.03)

    No; label says effects on heart failure are not established

    The pattern is clear: the overall 20% reduction was driven mainly by fewer heart attacks. Cardiovascular death and stroke trended lower, but their confidence intervals cross 1.0.

    Is the Heart Benefit Just From Weight Loss?

    Probably not entirely, although the evidence here comes from secondary analyses and should be read with care. People on semaglutide lost 9.39% of their body weight at 104 weeks, compared with 0.88% on placebo. See how much weight you can lose on Wegovy.

    A 2025 Lancet analysis by Deanfield, Lincoff and colleagues found the cardiovascular benefit across all starting weight and waist-size groups. Reduction in waist size explained about a third (33%) of the MACE benefit, which means roughly two-thirds was not accounted for by waist change. A separate post hoc analysis presented at the European Congress on Obesity in May 2025, released by Novo Nordisk, reported fewer MACE events within the first three months (HR 0.63, 95% CI 0.41-0.95), before much weight had been lost. Its confidence intervals were not adjusted for testing many outcomes, so it suggests rather than proves an early effect.

    What Did Later SELECT Analyses Find About Heart Failure, Kidneys and Frailty?

    1. 1Heart failure: in a 2024 Lancet analysis of 4,286 participants who had heart failure at the start, MACE occurred in 9.1% on semaglutide versus 12.3% on placebo, and cardiovascular death was 24% lower. This was a subgroup analysis, and the FDA label still states that effects on heart failure have not been established.
    2. 2Kidneys: a 2024 Nature Medicine analysis found a composite kidney outcome in 1.8% versus 2.2% (HR 0.78, 95% CI 0.63-0.96), driven mainly by less heavy protein loss in the urine and fewer large drops in kidney filtration (eGFR). At 104 weeks, eGFR was 0.75 mL/min/1.73m² higher with semaglutide.
    3. 3Frailty: a JAMA Cardiology analysis published September 17, 2026, found no significant difference in the MACE benefit by frailty level (interaction P=.09).

    How Many People Stopped Wegovy in SELECT, and Why?

    Stopping was common. In the NEJM paper, 16.6% of people on semaglutide stopped the drug because of adverse events, compared with 8.2% on placebo. The FDA label reports that 31% on Wegovy and 27% on placebo stopped treatment permanently for any reason. Serious adverse events were less common with semaglutide (33.4% versus 36.4%).

    The benefit was seen in people who stayed on treatment for years. What happens to weight and other measures after stopping is covered in what happens when you stop taking Wegovy, and broader safety questions in GLP-1 long-term side effects.

    What Does the FDA Label Say About Wegovy and Cardiovascular Risk?

    The FDA approved Wegovy on March 8, 2024, to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, alongside a reduced-calorie diet and more physical activity. As of the label revised in May 2026, this heart indication applies to both the Wegovy injection and Wegovy tablets; the differences between the two forms are covered in Wegovy pill vs injection.

    According to the label, the injection is started at 0.25 mg weekly and increased every four weeks through 0.5, 1 and 1.7 mg to a maintenance dose of 2.4 mg weekly (or 1.7 mg). The tablets start at 1.5 mg daily and step up every 30 days through 4 and 9 mg to 25 mg daily from day 91. See the Wegovy dosing schedule for missed doses.

    Does Wegovy Raise Your Heart Rate?

    Yes, slightly on average, and the label lists this as a warning. In adults, average resting heart rate rose by 1 to 4 beats per minute compared with placebo. Larger increases were more common on Wegovy: a maximum increase of 10 to 19 beats per minute occurred in 41% versus 34% on placebo, and an increase of 20 beats per minute or more in 26% versus 16%. In children and teenagers, increases of 20 or more occurred in 54% versus 39%. The label advises stopping the drug if a sustained increase in resting heart rate occurs. Other side effects of the tablet form are listed in Wegovy pill side effects.

    Does Medicare Cover Wegovy for Heart Disease?

    The heart indication changed the coverage picture. Medicare Part D has long excluded drugs used only for weight loss, but CMS said in March 2024 that Part D plans may cover Wegovy when it is prescribed for its cardiovascular indication. Medicaid programs must cover the cardiovascular use, though states may apply rules such as prior authorization. The Medicare GLP-1 Bridge began July 1, 2026. Plan rules on prior authorization and cost vary. For private plans, see does insurance cover Wegovy.

    Ways Medicare and Medicaid may cover Wegovy, as of November 2026

    Coverage route
    Who qualifies
    Cost
    Dates and source

    Medicare Part D, cardiovascular indication

    Adults with established cardiovascular disease plus obesity or overweight, prescribed for heart-risk reduction

    Depends on the plan

    Allowed since March 2024 (CMS guidance)

    Medicare GLP-1 Bridge

    Eligibility criteria include BMI 27 or higher with prior heart attack, stroke or symptomatic PAD; uses that basic Part D can already cover, including the heart indication, are excluded

    $50 copay, outside the regular Part D benefit

    July 1, 2026 to December 31, 2027 (CMS); covers Wegovy injection, Wegovy tablets and Zepbound

    Medicaid, cardiovascular indication

    Enrollees meeting the cardiovascular indication

    Set by each state

    States must cover; may use utilization management (CMS, March 2024)

    CMS also says the BALANCE model is not launching in Part D in 2027 (page updated July 13, 2026). Because the Bridge excludes uses already coverable under basic Part D, a prescription for the heart indication is generally expected to go through your regular Part D plan.

    What the SELECT Trial Doesn't Tell You

    1. 1Whether Wegovy prevents a first heart attack or stroke in people without existing cardiovascular disease.
    2. 2How it works in people with type 2 diabetes, who were excluded.
    3. 3Whether it lowers cardiovascular death or stroke on their own; neither reached statistical significance.
    4. 4How it compares with tirzepatide (Zepbound) for heart outcomes; SELECT compared semaglutide only with placebo. For weight results, see Zepbound vs Wegovy.
    5. 5Benefits beyond the roughly 3.5 years of follow-up.

    When to Talk to Your Doctor

    1. 1You have had a heart attack, stroke or peripheral artery disease and have a BMI of 27 or more, and want to know whether Wegovy fits your plan.
    2. 2You notice a racing or pounding heartbeat at rest that does not settle.
    3. 3You have chest pain, shortness of breath or stroke symptoms; call emergency services right away.
    4. 4Nausea, vomiting or diarrhea make it hard to stay on the medicine or keep fluids down.
    5. 5You are thinking of stopping Wegovy or changing your other heart medicines.

    Questions to Ask Your Doctor About Wegovy and Your Heart

    1. 1Do I meet the label criteria for the cardiovascular indication, and will you write that on the prescription?
    2. 2What is my own risk of a heart attack or stroke, and how much might Wegovy lower it in absolute terms?
    3. 3Should Wegovy be added to my current statin, blood pressure or blood-thinning medicines, not replace them?
    4. 4Does my Part D plan cover Wegovy for the heart indication, and does it need prior authorization?
    5. 5How will we monitor my heart rate and side effects during dose increases?

    The Bottom Line

    In the Novo Nordisk-funded SELECT trial, Wegovy reduced major cardiovascular events by 20% in relative terms (from 8.0% to 6.5%) in adults with existing cardiovascular disease and overweight or obesity who did not have diabetes. The benefit came mainly from fewer non-fatal heart attacks; cardiovascular death and stroke did not fall significantly on their own, and the label says heart failure effects are not established. About 1 in 6 people stopped because of side effects. As of November 2026, both forms are FDA-approved for this use, and Part D plans may cover it. If you have heart disease, ask your cardiologist whether it fits your treatment.

    FAQ

    In the SELECT trial, non-fatal heart attacks were 28% less frequent (HR 0.72), and this was the only part of the main outcome that was statistically significant on its own. The overall reduction in heart attack, stroke and cardiovascular death combined was 20%.

    SELECT was a Novo Nordisk-funded trial of 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more, without diabetes. It compared weekly semaglutide 2.4 mg with placebo for an average of about 40 months.

    Wegovy is approved to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and obesity or overweight. The FDA approved this in March 2024, and the May 2026 label covers both injection and tablets.

    Medicare Part D plans may cover Wegovy when prescribed for its cardiovascular indication, under CMS guidance from March 2024. Coverage details, prior authorization and costs depend on the plan.

    Yes, by 1 to 4 beats per minute on average in adults. Increases of 20 beats per minute or more occurred in 26% on Wegovy versus 16% on placebo. Stop and contact your doctor if your resting heart rate stays high.

    A SELECT subgroup analysis in people with heart failure found fewer cardiovascular events, but the FDA label states that effects on heart failure have not been established, and the label's heart failure result was not statistically significant.

    Sources

    This article summarizes published research and regulatory information for general information and is not medical advice. The SELECT trial and its follow-up analyses were funded by Novo Nordisk, the maker of Wegovy.

    Diana Gangan

    Author

    Published November 8, 2026
    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    GLP-1 Drugs Explained: Types, Benefits, Risks, and How They Help With Weight Loss